艾瓦布拉丁对住院急性心力衰竭患者的影响:单一中心回顾性研究
Mahmoud Abdelnabi1, Juthipong Benjanuwattra1, Yehia Saleh2
1Internal Medicine Department, Texas Tech University Health Science Center Lubbock, Texas, USA.
American journal of cardiovascular disease
|July 20, 2023
概括
在急性不补偿性心力衰竭患者中使用伊瓦布拉丁并没有减少再住院治疗或死亡率. 然而,它与较低的平均心率和更短的住院时间有关.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心率增加 (HR) 在不补偿性心力衰竭 (DHF) 中是有害的.
- 伊瓦布拉丁已被批准用于慢性心力衰竭与减少喷射率 (HFrEF).
- 关于伊瓦布拉丁在急性不补偿性心力衰竭 (ADHF) 中的疗效和安全性的数据有限.
研究的目的:
- 调查伊瓦布拉丁对住院ADHF患者的发病率和短期死亡率的影响.
- 评估伊瓦布拉丁对心率和住院时间的影响.
主要方法:
- 对998名ADHF患者进行了回顾性观察性研究,这些患者接受了指导方针导向的治疗,包括β抑制剂.
- 患者被分为两组:单独使用β-阻断剂 (无-伊瓦布拉丁) 或β-阻断剂加伊瓦布拉丁.
- 倾向匹配用于控制混因素;血液动力学不稳定的患者被排除在外.
主要成果:
- 两组之间基线特征,实验室或心声学数据没有显著差异.
- 伊瓦布拉丁组的平均HR显着较低 (87±15bpm vs. 90±12bpm),住院时间较短 (5.3±2.3天 vs. 7.7±5.6天).
- 在1个月和6个月的随访期间,再住院或死亡率没有显著差异.
结论:
- 在住院的ADHF患者中,伊瓦布拉丁的使用与平均HR和住院时间的减少有关.
- 伊瓦布拉丁在1个月和6个月的随访中没有显示出降低再住院或死亡率的益处.
更多相关视频
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.5K
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
3.7K
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
628
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
628
01:22Heart Failure Drugs: β-Blockers
364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
465
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
876
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
876
01:30Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14
01:22Heart Failure Drugs: Diuretics
423
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
423